Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 7/20 | 0.46 |
| ▸ | ADK | P55263 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023830 | 1.00 | TYMP (0.46) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL22381870 | 1.00 | TYMP (0.46) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL18521074 | 1.00 | TYMP (0.46) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL23023831 | 0.94 | TYMP (0.46) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL28627963 | 0.91 | TYMP (0.40) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL23023832 | 0.90 | TYMP (0.39) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL23023837 | 0.90 | TYMP (0.56) | TYMPADKPRMT5WDR77METTL3 | |
| SCHEMBL21305068 | 0.90 | TYMP (0.55) | TYMP | |
| SCHEMBL8381924 | 0.90 | TYMP (0.55) | TYMP | |
| SCHEMBL19493438 | 0.90 | TYMP (0.55) | TYMP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044206-A1 | CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS | STING1, CGAS, IFNAR1 | TYMP 1508/4885ADK 471/4885PRMT5 4089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.